SpringWorks Therapeutics Inc

NASDAQ:SWTX 4:00:00 PM EDT

42.47

-1.64 (-3.72%)

7:46:23 PM EDT: $42.40 -0.07 (-0.17%)

Market Cap (Intraday)	3.13B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$11.07 Million
Adjusted EPS	-$1.19

See more estimates

10-Day MA	$43.92
50-Day MA	$47.89
200-Day MA	$33.91

See more pivots

SpringWorks Therapeutics Inc Stock, NASDAQ:SWTX

100 Washington Boulevard, Stamford, Connecticut 06902

United States of America

Phone: +1.203.883.9490

Number of Employees: 305

http://www.springworkstx.com

Description

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.